Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00509041 · OUTCOME

Number of Participants With Overall Tumor Response

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma · Source last updated 2016-08-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
Duration of study until progression (up to 3 years)

What was measured

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: * Complete Response (CR): disappearance of all target lesions; * Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; * Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; * Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs.

Groups in this outcome

Dasatinib

Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Dasatinib43

Reported measurements

Complete Response
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dasatinib0Not reportedNot reportedNot reportedNot reported
Partial Response
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Dasatinib2Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
    title
    Complete Response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        2
    title
    Partial Response
denoms
  1. counts
    1. group Id
      OG000
      value
      43
    units
    Participants
description
Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: * Complete Response (CR): disappearance of all target lesions; * Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; * Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; * Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs.
groups
  1. description
    Use of dasatinib (50 mg orally twice a day) in treatment of pts with previously treated malignant mesothelioma
    id
    OG000
    title
    Dasatinib
param Type
NUMBER
reporting Status
POSTED
time Frame
Duration of study until progression (up to 3 years)
title
Number of Participants With Overall Tumor Response
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice